Last reviewed · How we verify
NCT05667350
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)
trial testing Blood drawing in Biliary Tract Cancer in 492 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Eastern Hepatobiliary Surgery Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 492 |
| Start date | 28 February 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Blood drawing
- Blood drawing
Conditions studied
- Biliary Tract Cancer — all drugs for Biliary Tract Cancer →
Sponsor
Eastern Hepatobiliary Surgery Hospital
Who can join
Adults 40 to 75, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ASCEND-BTC is a prospective, multi-center, observational study aimed at detecting early biliary tract cancer by combined assays of serum protein and cell-free DNA (cfDNA) methylation. The study will enroll approximately 492 participants diagnosed with biliary tract cancer and benign diseases.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.
Ranganathan K, Kurian NS, Goswami HM, Rishi KD, et al · · 2024 · cited 5× · PMID 40027943 · DOI 10.1016/j.jlb.2024.100150
Verify or expand the search:
- PubMed search for NCT05667350
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood drawing
Trials testing the same drug.
- NCT05989555 — Effects of Radioactive Iodine on the Immune System in Thyroid Cancer · unknown
- NCT06139042 — Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers · recruiting
- NCT04717219 — Myeloid Cells in Aortic Valve Stenosis · unknown
- NCT04100122 — Luminex-based Assay to Identify Major IgE-binding Episode Among IgE-mediated Wheat-allergic Patient · completed
- NCT03870828 — Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study · unknown
Other recruiting trials for Biliary Tract Cancer
Currently open trials in the same condition.
- NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
- NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
- NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
- NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
- NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting
Other Eastern Hepatobiliary Surgery Hospital trials
Trials by the same sponsor.
- NCT07363356 — Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer · Phase 2 · not yet recruiting
- NCT07351513 — A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma · Phase 2 · not yet recruiting
- NCT07351591 — A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers · Phase 2 · not yet recruiting
- NCT07285850 — The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD · Phase 2, PHASE3 · recruiting
- NCT06902389 — A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05667350 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eastern Hepatobiliary Surgery Hospital
- Last refreshed: 30 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667350.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing